Tirzepatide
Also known as: Mounjaro, Zepbound, GIP/GLP-1 dual agonist
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
A dual GIP and GLP-1 receptor agonist with FDA approvals for type 2 diabetes and chronic weight management, supported by large randomized trials.
What it is & how it works
What it is
Tirzepatide is a dual agonist: a single molecule that activates both the GIP and GLP-1 receptors, two gut-hormone pathways involved in insulin release and appetite. It is FDA-approved and well-studied in humans.
How it works
Combining GIP and GLP-1 activity, tirzepatide improves glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite. The dual mechanism is the headline difference from GLP-1-only agents like semaglutide.
The evidence
The SURPASS (diabetes) and SURMOUNT (weight) programs are large randomized controlled trials, some directly comparing tirzepatide to a GLP-1-only drug. As with semaglutide, this places it firmly in the human-evidence tier — and firmly in the category of prescription medicine that should be managed by a clinician.
What it's discussed & studied for
- Type 2 diabetes (approved)
- Chronic weight management (approved)
Discussion of a use is not a claim that it works or is approved.
Research status
FDA-approved and backed by the SURPASS (diabetes) and SURMOUNT (weight) randomized trial programs.
Evidence quality
High: large randomized controlled human trials, including active-comparator studies against GLP-1-only agents.
Dosing discussion
Approved products use a stepwise titration to limit gastrointestinal effects. Dosing belongs with a prescribing clinician and the label, not community protocols.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
Side effects are predominantly gastrointestinal. It carries labeled warnings (including a boxed thyroid C-cell tumor warning from rodent data). Prescription drug — use under supervision.
Sourcing literacy
Approved tirzepatide is prescription-only. Gray-market or compounded versions are a recurring FDA enforcement subject and carry identity/purity/dosing risk.
Selected literature
FAQ
What makes tirzepatide 'dual'?
It activates both the GIP and GLP-1 receptors, whereas semaglutide targets GLP-1 alone. In trials this dual action produced strong glucose and weight effects.
Is it approved?
Yes, for type 2 diabetes and for chronic weight management under separate brand names.